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Eric R. Bates, MD
T he debate about the advantages of fibrinolytic therapy orprimary percutaneous coronary angioplasty (PCI) as a
superior reperfusion strategy for ST-elevation myocardial
infarction (STEMI) has continued for 30 years. In the first
decade, primary PCI was limited by first-generation equip-
ment, inadequate radiographic imaging systems, suboptimal
adjunctive antithrombotic therapy, and delays in time-to-
treatment. Successful reperfusion rates were too low and
infarct artery reocclusion and restenosis rates were too high,
so fibrinolytic therapy was associated with better clinical
outcomes.1 Since then, fibrinolytic therapy improvements
have included bolus administration of newer agents, adjunc-
tive dual antiplatelet therapy with aspirin and clopidogrel, and
cardiac catheterization as soon as possible for reperfusion
failure and within 24 hours after successful reperfusion to
maximize sustained infarct artery patency rates.2 Perhaps
more impressive has been the improvement in primary PCI
that now makes it the preferred reperfusion strategy.3 The PCI
wires and catheters are well engineered, radiographic and
intravascular imaging capability allows excellent visualization
of the coronary arteries, antithrombotic medications decrease
the risk of acute closure, and drug-eluting stents assure
excellent long-term infarct artery patency rates. Most impor-
tantly, pre-hospital and in-hospital systems of care have been
developed to decrease time-to-treatment and offer reperfu-
sion therapy to almost all patients with STEMI unless
treatment is deemed futile.4
Lost in the debate over which reperfusion strategy best
reduces mortality rates is the important reduction in morbidity
associated with both reperfusion therapies compared with
historical controls. Hemodynamic, electrical, mechanical, and
thrombotic complications have all been reduced by successful
reperfusion therapy that restores microvascular perfusion,
limits infarct size, and improves left ventricular remodeling. A
leading cause of death before reperfusion therapy was
myocardial rupture, defined for the purposes of this discus-
sion as free-wall rupture or ventricular septal rupture and
excluding papillary muscle rupture or left ventricular pseud-
oaneurysm formation from contained free-wall rupture.
The incidence of myocardial rupture is difficult to ascertain
because death can occur before hospital admission, failed
diagnosis is possible unless routine echocardiography is
performed, and autopsy rates have been poor and variable.
Some patients have certainly been misclassified as sudden
cardiac death or cardiogenic shock due to myocardial
necrosis. Rates as high as 6% for myocardial rupture and 3%
for ventricular septal rupture were reported in the pre-
reperfusion era. More recently, the risk in the reperfusion era
appears to be approximately 2% for myocardial rupture and
0.3% for ventricular septal rupture.5,6 The clinical diagnosis of
free-wall rupture is suggested by the physical findings of
cardiac tamponade (Beck’s triad of hypotension, jugular
venous distension, and muffled heart sounds; pulsus para-
doxus), electrical mechanical dissociation in the absence of
preceeding heart failure, or hypotension with at least a
moderate pericardial effusion on echocardiography. The
clinical diagnosis of ventricular septal rupture is suggested
by a systolic murmur and confirmed by an abnormal oxygen
saturation run during pulmonary artery catheterization, color
flow Doppler echocardiography, or contrast left ventriculog-
raphy. Pathologic confirmation of myocardial rupture can also
be obtained during surgery or necropsy. Risk for myocardial
rupture is increased with first myocardial infarction (MI),
anterior MI, older age, female sex, absence of prior angina or
MI, hypertension, no or unsuccessful reperfusion therapy, late
reperfusion therapy, and one-vessel disease without collateral
circulation. Prognosis is poor with mortality rates of 75% to
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90% with free-wall rupture and 40% to 75% with ventricular
septal rupture.
It has previously been noted several times that reperfusion
therapy has decreased the incidence of myocardial rupture.
Figueras and collegues reported on 425 patients with
myocardial rupture due to STEMI over a 30-year period from
a single-center prospective MI registry including 6678 Span-
ish patients.7 Free-wall rupture occurred in 280 patients and
ventricular septal rupture occurred in 145 patients. The 6.2%
incidence during the first 5 years decreased to 3.2% during
the last 5 years as the use of reperfusion therapy increased
from 0% to 75%. The rate of death declined from 94% to 75%,
despite an increase in mean age from 66 to 75 years, in
parallel with other improvements in medical therapy and the
increasing delivery of primary PCI and surgical therapy.
In this issue of the Journal of the American Heart
Association, Honda and colleagues investigated temporal
trends in the incidence and clinical and pathological charac-
teristics of myocardial rupture in patients with acute MI.8
Their single-center prospective MI registry included 5699
Japanese patients who were divided into 3 cohorts by
admission year: 1977-1989, 1990-2000, 2001-2011. There
were 144 (2.5%) patients with myocardial rupture, with 45
survivors. The incidence of myocardial rupture decreased over
time (3.3% to 1.7%) as reperfusion therapy rates increased
(2.5% to 70.1%); mortality rates decreased over time (90% to
50%) as emergency surgical rates increased (39% to 74%).
Risk factors for myocardial rupture included first MI, anterior
MI, female sex, older age, and hypertension. The incidence of
myocardial rupture declined from 3.3% without reperfusion
therapy to 2.9% with fibrinolytic therapy to 1.2% with primary
PCI, but in 64 autopsy cases, the myocardial hemorrhage rate
was 83% with primary PCI, compared with 71% for fibinolysis
and 18% with no reperfusion therapy. The authors concluded
that reperfusion therapy, particularly primary PCI, has
decreased the incidence of myocardial rupture and that
surgical therapy has increased survival rates.
The change in baseline characteristics over time in the
Japanese registry is stunning. If there was no ascertainment
bias, the increase in the incidence of hypertension from 32%
to 69%, hyperglycemia from 19% to 55%, and hyperlipidemia
from 6% to 57% reflects a dramatic shift in atherosclerosis risk
factors that portends a major increase in the risk for coronary
artery disease in Japan. Similarly, the more recent use of
primary PCI in almost 70% of patients and emergency surgery
in a similar percentage of patients with myocardial rupture
reflects increased utilization of invasive therapies.
The incidence of myocardial rupture in the Japanese
registry was half that reported in the Spanish registry,
perhaps because patients were younger, time-to-treatment
was earlier, and patients with non-ST elevation MI were
included. The outcomes over time trended similarly and both
reports suggested that the benefit was due to increased use
of reperfusion therapy, particularly primary PCI. The Japanese
report more precisely shows the benefit with primary PCI
versus fibrinolytic therapy and adds an important pathological
observation.
Becker and van Mantgem defined 3 types of cardiac
rupture after MI.9 Type I rupture occurs within 24 hours as an
abrupt, slit-like tear. Type II rupture occurs as a later tear from
progressive myocardial erosion. Type III rupture occurs in
older infarctions as a perforation within a thin walled
aneurysm. In the pre-reperfusion era, Type III rupture was
most common and required transmural myocardial necrosis
with hemorrhagic transformation in the central region of
necrosis where microvascular damage had resulted. It began
either at the endocardial surface or within the myocardium
and dissected through the infarct zone to the epicardial
surface. The highest risk period was 3 to 5 days after MI. In
the reperfusion era, Type I and Type II ruptures appear to be
most common, with the highest risk in the first 1 to 2 days.
Hemorrhage into a nontransmural infarction may weaken the
supporting framework of the infarct zone and increase the risk
of cardiac rupture through hemorrhagic dissection or delayed
healing. The risk is increased with late administration of
fibrinolytic therapy.10 Thus, reperfusion therapy decreases the
overall risk of myocardial rupture by decreasing the extent
and transmurality of myocardial necrosis, but it may increase
early risk due to intramyocardial hemorrhage. The risk of
myocardial hemorrhage was previously attributed to fibrino-
lytic therapy as a unique complication and used as another
point in the debate in favor of primary PCI.11 The observation
by Honda and colleagues that the risk for myocardial
hemorrhage is similar with fibrinolytic therapy or primary
PCI is new and challenging. Evidently, myocardial hemorrhage
is present in at least 25% of patients after primary PCI,
suggesting that new research is required to target potential
therapies for this complication of reperfusion therapy.12
Emergency stabilizing therapy for myocardial rupture
includes volume resuscitation, pressors, pericardiocentesis
for free-wall rupture, and intra-aortic balloon counterpulsation
for ventricular septal rupture. Beta-blockers were initially
observed to decrease the risk of myocardial rupture in the
first International Study of Infarct Survival (ISIS-1) trial, but the
benefit is less clear now in the reperfusion era.13 Myocardial
rupture is usually rapidly fatal, but surgery can be undertaken
in stabilized patients if feasible. Earlier surgery makes clinical
sense, but cardiac surgeons prefer to operate later using
natural history as a selection process to decrease the high
surgical mortality rates. Better results would be predicted in
patients younger than 80 years and without cardiogenic
shock. The utility of other hemodynamic support devices and
transcatheter ventricular septal closure devices remains to be
determined.14,15
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